PRINCETON, N.J. & PARIS--(BUSINESS WIRE)--STENTYS S.A. (STNT.PA), a medical technology company commercializing the world's first and only self-apposing stent to treat Acute Myocardial Infarction (AMI), announced today that Gilles Montalescot, M.D., PhD, has joined its Scientific Advisory Board (SAB).
